Introduction {#S0005}
============

Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system. Although the exact aetiology of MS remains unclear, it is likely caused by dysregulation of the immune system leading to injury of the nervous system which is triggered through a multifactorial pathway of genetic predisposition and environmental triggers (e.g. geographic latitude, vitamin D deficiency, viruses, and smoking) \[[@CIT0001], [@CIT0002]\]. With an age onset of 20--40, overall incidence rate of MS is 3.6 cases per 100,000 person-years in women and 2.0 in men \[[@CIT0003]\].

Several therapeutic options are available for MS including interferon beta, glatiramer acetate, immunomodulators, mitoxantrone, and monoclonal antibodies (MAbs). The MAbs, as monospecific antibodies against certain pro inflammatory/inflammatory molecules, are currently used in many autoimmune disorders and have shown great potential for treatment of MS \[[@CIT0004]\].

The α4β1 integrin is a cell adhesion molecule on the surface of lymphocytes and monocytes that mediates adherence and migration of leukocytes through the blood brain barrier. Natalizumab, a humanized monoclonal antibody, binds to α4 integrins and inhibits the integrin-induced inflammatory pathway \[[@CIT0005], [@CIT0006]\].

Following Food and Drug Administration (FDA) approval of natalizumab for treatment of MS in November 2004, it was withdrawn from the market in February 2005 because two patients who received natalizumab in combination with interferon-β1a developed progressive multifocal leukoencephalopathy (PML) with one death \[[@CIT0007], [@CIT0008]\]. Natalizumab was conditionally re-approved in June 2006 after no additional cases of PML were reported. Current guidelines recommend reserving natalizumab for patients with aggressive initial presentation or refractory to other therapies. In addition, use of natalizumab in combination with interferon is discouraged \[[@CIT0009]\].

Until this time, no meta-analysis on the efficacy and/or tolerability of natalizumab in relapsing MS has been conducted. In the present work, by evaluating all randomized controlled trials a meta-analysis was conducted to reach a better conclusion about the efficacy and tolerability of this new promising medication for MS.

Material and methods {#S0006}
====================

Data sources {#S20007}
------------

PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched for studies investigated the efficacy and/or tolerability of natalizumab in multiple sclerosis. Data were collected from 1966 to 2008 (up to October). The search terms were: "multiple sclerosis" or "MS" and "natalizumab". The language was restricted to English. The reference list from retrieved articles was also reviewed for additional applicable studies.

Study selection {#S20008}
---------------

Controlled trials investigating the efficacy and/or tolerability of natalizumab in patients with MS were considered. "Mean change in Expanded Disability Status Scale (EDSS)", "number of patients with at least one relapse", and "number of patients with at least one new gadolinium (Gd)-enhancing lesion" were the key outcomes of interest for assessment of efficacy. "Any adverse events", "serious adverse events", "death", and "withdrawal because of adverse events" were the key outcomes for tolerability. We evaluated all published studies as well as abstracts presented at meetings. Three reviewers independently examined the title and abstract of each article to eliminate duplicates, reviews, case studies, and uncontrolled trials. Trials were disqualified if they were not placebo-controlled or their outcomes did not consider efficacy or tolerability. The reviewers independently extracted data on patients' characteristics, therapeutic regimens, dosage, trial duration, and outcome measures. Disagreements, if any, were resolved by consensus.

Assessment of trial quality {#S20009}
---------------------------

Jadad score, which evaluates studies based on their description of randomization, blinding, and dropouts (withdrawals), was used to assess the methodological quality of the trials \[[@CIT0010]\]. The quality scale ranges from 0 to 5 points with a low quality report of score 2 or less and a high quality report of score at least 3.

Statistical analysis {#S20010}
--------------------

Data from selected studies were extracted in the form of 2 × 2 tables. All included studies were weighted and pooled. The data were analysed using StatsDirect (2.7.2). Relative risk (RR) and 95% confidence intervals (95% CI) were calculated using Mantel-Haenszel and DerSimonian-Laird methods. The Cochran Q test was used to test for heterogeneity. The event rate in the experimental (intervention) group against the event rate in the control group was demonstrated using L\'Abbe plot as an aid to explore the heterogeneity of effect estimates. Funnel plots were used as an indicator for publication bias.

Results {#S0010}
=======

The electronic searches yielded 1547 items: 241 from PubMed, 20 from Cochrane Central, 446 from Web of Science, and 840 from Scopus. Of those, 9 trials were scrutinized in full text. Five reports were considered ineligible while 4 trials \[[@CIT0011]--[@CIT0014]\] were included in the analysis ([Figure 1](#F0001){ref-type="fig"}). All 4 trials received a Jadad score of 3 or more in assessment of trial quality ([Table I](#T0001){ref-type="table"}). Patients' characteristics, type of MS, mean EDSS before trial, dosage of natalizumab, and duration of treatment/follow-up for each study are reported in [Table II](#T0002){ref-type="table"}. This meta-analysis included 1407 patients with relapsing MS randomized to receive either natalizumab or placebo. All trials included in the current meta-analysis were randomized and double blinded and patients were diagnosed with relapsing MS according to EDSS score and magnetic resonance imaging (MRI) results.

![Flow diagram of the study selection process](AMS-6-14653-g001){#F0001}

###### 

Jadad quality score of randomized controlled trial included in the meta-analysis

  Study                      Factors and Jadad score           
  -------------------------- ------------------------- --- --- ---
  Polman *et al*., 2006      2                         2   1   5
  O\'Connor *et al*., 2004   1                         2   1   4
  Miller *et al*., 2003      2                         1   0   3
  Tubridy *et al*., 1999     1                         2   1   4

###### 

Characteristics of papers included in the meta-analysis

  Study                      Mean age   Sex (No.)   Type of MS   EDSS         Dosage of natalizumab   Duration of treatment/follow-up \[weeks\]                                           
  -------------------------- ---------- ----------- ------------ ------------ ----------------------- ------------------------------------------- --------------------------------------- ----
  Polman *et al*., 2006      36         660         282          RRMS         2.3 ±1.2                2.3 ±1.2                                    300 mg every 4 weeks                    48
  O\'Connor *et al*., 2004   39.5       147         33           RRMS, SPMS   1 mg: 4.5 3 mg: 4.3     4.5                                         Single infusion of 1 mg/kg or 3 mg/kg   45
  Miller *et al*., 2003      43.9       152         61           RRMS, SPMS   3 mg: 4.2 6 mg: 4.3     4.4                                         3 mg/kg or 6 mg/kg every 4 weeks        24
  Tubridy *et al*., 1999     40.4       46          26           RRMS, SPMS   4.9                     4.7                                         2 infusions of 3 mg/kg 4 weeks apart    24

*MS -- multiple sclerosis, EDSS -- Expanded Disability Status Scale, RRMS -- relapsing remitting multiple sclerosis, SPMS -- secondary progressive multiple sclerosis*

Efficacy {#S20011}
--------

Pooled RR for at least 1 relapse in 4 trials including all doses \[[@CIT0011]--[@CIT0014]\] was 0.7 with 95% CI of 0.42 to 1.17 and a non-significant RR (*p* = 0. 17, [Figure 2A](#F0002){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are heterogeneous (*p* = 0.0065, [Figure 2B](#F0003){ref-type="fig"}) and could not be combined; thus, the random effects for individual and summary of RR were applied. Regression of normalized effect versus precision for all included studies for relapse among natalizumab vs. placebo therapy was 2.02 (95% CI = −5.47 to 9.51, *p* = 0.37), and Kendall\'s test on standardized effect vs. variance indicated tau = 0.67, *p* = 0.33 ([Figure 2C](#F0004){ref-type="fig"}).

![Individual and pooled relative risk for the outcome of "at least one relapse" in the studies considering natalizumab vs. placebo therapy in all doses](AMS-6-14653-g002){#F0002}

![Heterogeneity indicators for the outcome of "at least one relapse" in the studies considering natalizumab vs. placebo therapy in all doses](AMS-6-14653-g003){#F0003}

![Publication bias indicators for the outcome of "at least one relapse" in the studies considering natalizumab vs. placebo therapy in all doses](AMS-6-14653-g004){#F0004}

Summary RR for at least 1 relapse in 2 trials in which 3 mg/kg or 6 mg/kg or 300 mg every 4 weeks were administered for therapy \[[@CIT0011], [@CIT0013]\] was 0.5 with a 95% CI of 0.42--0.61, a significant RR (*p* \< 0.0001, [Figure 3A](#F0005){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are homogenous (*p* = 0.98, [Figure 3B](#F0006){ref-type="fig"}) and could be combined but because of few included studies, the random effects for individual and summary of RR were applied. Regression of normalized effect vs. precision for all included studies for clinical response among natalizumab vs. placebo therapy could not be calculated because of too few strata.

![Individual and pooled relative risk for the outcome of "at least one relapse" in the studies considering natalizumab vs. placebo therapy in doses of 3 or 6 mg/kg or 300 mg every 4 weeks](AMS-6-14653-g005){#F0005}

![Heterogeneity indicators for the outcome of "at least one relapse" in the studies considering natalizumab vs. placebo therapy in doses of 3 or 6 mg/kg or 300 mg every 4 weeks](AMS-6-14653-g006){#F0006}

The summary RR for at least 1 new Gd-enhancing lesion in 2 trials \[[@CIT0011], [@CIT0013]\] was 0.22 with a 95% CI of 0.05--1.01 and a non-significant RR (*p* = 0.051, [Figure 4A](#F0007){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are heterogeneous (*p* \< 0.0001, [Figure 4B](#F0008){ref-type="fig"}) and could not be combined; thus the random effects for individual and summary of RR were applied. Regression of normalized effect vs. precision for all included studies for clinical response among natalizumab vs. placebo therapy could not be calculated because of too few strata.

![Individual and pooled relative risk for the outcome of "at least one new Gd-enhancing lesion" in the studies considering natalizumab vs. placebotherapy](AMS-6-14653-g007){#F0007}

![Heterogeneity indicators for the outcome of "at least one new Gd-enhancing lesion" in the studies considering natalizumab vs. placebo therapy](AMS-6-14653-g008){#F0008}

Mean change in EDSS was reported in 3 trials \[[@CIT0011], [@CIT0012], [@CIT0014]\]; but only 1 trial \[[@CIT0012]\] reports standard deviation of the mean ([Table III](#T0003){ref-type="table"}), leaving us with insufficient data to pool the results.

###### 

Outcomes

  Study                      Mean change in EDSS             No. of patients with at least one relapse   No. of patients with at least one new Gd-enhancing lesion                      
  -------------------------- ------------------------------- ------------------------------------------- ----------------------------------------------------------- --------- -------- ---------
  Polman *et al*., 2006      --                              --                                          126/627                                                     126/315   22/627   102/315
  O\'Connor *et al*., 2004   1 mg:−1.5 ±1.5 3 mg:−1.3 ±1.4   −1.5 ±1.5                                   4/117                                                       2/63      --       --
  Miller *et al*., 2003      3 mg:−0.14 6 mg:−0.03           +0.03                                       27/142                                                      27/71     43/142   48/71
  Tubridy *et al*., 1999     −0.04                           +0.02                                       18/37                                                       12/35     --       --

Tolerability {#S20012}
------------

[Table IV](#T0004){ref-type="table"} shows the number of patients with any adverse events, serious adverse events, and withdrawal because of adverse events in both the natalizumab group and the placebo group in each trial. Type of serious and common adverse events, and cause of death are demonstrated in [Table V](#T0005){ref-type="table"}. As shown, 3 deaths have been reported from 2 trials \[[@CIT0011], [@CIT0013]\]. In Polman\'s trial \[[@CIT0013]\], 2 deaths occurred during the study, both in the natalizumab group. One patient, who died of malignant melanoma, had a history of malignant melanoma and had noted a new lesion at the time of receiving the first dose of natalizumab; he had received a total of 5 doses of natalizumab before receiving a confirmed diagnosis. A second patient died of alcohol intoxication after having received 25 doses of natalizumab. Another death was reported in Miller\'s study \[[@CIT0011]\] because of pleural carcinomatosis complicated by haemothorax.

###### 

Adverse events

  Study                      Any adverse events   Serious adverse events   Death    Withdrawal because of adverse events                            
  -------------------------- -------------------- ------------------------ -------- -------------------------------------- ------- ------- -------- -------
  Polman *et al*., 2006      596/627              300/312                  56/627   75/312                                 2/627   0/312   19/627   6/312
  O\'Connor *et al*., 2004   106/117              56/63                    --       --                                     --      --      --       --
  Miller *et al*., 2003      --                   --                       8/142    7/71                                   0/142   1/71    7/142    3/71
  Tubridy *et al*., 1999     32/37                34/35                    --       --                                     --      --      --       --

###### 

Type of adverse events

  Study                      Type of serious adverse events                                                  Type of common adverse events                                                   Cause of death                                                                                                                               
  -------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------- ---------------------------------------------------- ------------------------------------------ ------------------------
  Polman *et al*., 2006,     relapse of multiple sclerosis cholelithiasis, need for rehabilitation therapy   relapse of multiple sclerosis, cholelithiasis need for rehabilitation therapy   headache, fatigue, urinary tract infection   headache, fatigue, urinary tract infection           malignant melanoma, alcohol intoxication   --
  O\'Connor *et al*., 2004   --                                                                              --                                                                              Headache, pharyngitis,nausea                 headache, pharyngitis, dizziness, back pain          --                                         --
  Miller *et al*., 2003      anaphylactoid reaction, serum sickness                                          serum sickness                                                                  headache, infection, pharyngitis             headache, accidental injury, infection, myasthenia   --                                         pleural carcinomatosis

The summary RR for any adverse events of natalizumab vs. placebo therapy among 3 trials \[[@CIT0012]--[@CIT0014]\] was 0.99 with a 95% CI of 0.96--1.01, indicating a non-significant RR for natalizumab administration (*p* = 0.34, [Figure 5A](#F0009){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are not significantly heterogeneous (*p* = 0.29, [Figure 5B](#F0010){ref-type="fig"}) and the fixed effects for individual and summary of RR were applied. Regression of normalized effect vs. precision for all included studies for any adverse events among natalizumab vs. placebo therapy could not be calculated because of too few strata.

![Individual and pooled relative risk for the outcome of "any adverse events" in the studies considering natalizumab vs. placebo therapy](AMS-6-14653-g009){#F0009}
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The summary RR for serious adverse events of natalizumab vs. placebo therapy in 2 trials \[[@CIT0011], [@CIT0013]\] was 0.39 with a 95% CI of 0.29--0.52, indicating a significant RR for natalizumab administration (*p* \< 0.0001, [Figure 6A](#F0011){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are homogeneous (*p* = 0.41, [Figure 6B](#F0012){ref-type="fig"}) but because of few included studies, the random effects for individual and summary of RR were applied. Regression of normalized effect vs. precision for all included studies for any adverse events among natalizumab vs. placebo therapy could not be calculated because of too few strata.

![Individual and pooled relative risk for the outcome of "serious adverse events" in the studies considering natalizumab vs. placebo therapy](AMS-6-14653-g011){#F0011}

![Heterogeneity indicators for the outcome of "serious adverse events" in the studies considering natalizumab vs. placebo therapy](AMS-6-14653-g012){#F0012}

The summary RR for withdrawal due to adverse events by natalizumab vs. placebo therapy in two trials \[[@CIT0011], [@CIT0013]\] was 1.43 with a 95% CI of 0.68--3.02, indicating a non-significant RR for natalizumab administration (*p* = 0.35, [Figure 7A](#F0013){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are homogeneous (*p* = 0.7131, [Figure 7B](#F0014){ref-type="fig"}) and the random effects for individual and summary of RR were applied because of few included studies. Regression of normalized effect vs. precision for all included studies for any adverse events in natalizumab vs. placebo therapy could not be calculated because of too few strata.

![Individual and pooled relative risk for the outcome of "withdrawal due to adverse events" in the studies considering natalizumab vs. placebo therapy](AMS-6-14653-g013){#F0013}

![Heterogeneity indicators for the outcome of "withdrawal due to adverse events" in the studies considering natalizumab vs. placebo therapy](AMS-6-14653-g014){#F0014}

Discussion {#S0012}
==========

In the present study, the efficacy and tolerability of natalizumab were evaluated for the first time by meta-analysis technique. The results demonstrated non-priority of natalizumab over placebo in preventing relapse or occurrence of new Gd-enhancing lesions.

Since different drug regimens were administered to the patients in the included trials, only two trials were selected which had similar drug regimens and thus the analysis for these two trials was repeated \[[@CIT0011], [@CIT0013]\]. The results of this analysis showed that natalizumab was effective in preventing relapse and occurrence of new Gd-enhancing lesions when administered in 3 or 6 mg/kg doses every weeks. As shown in [Figures 3A](#F0005){ref-type="fig"} and [2A](#F0002){ref-type="fig"}, the regimen of 3 or 6 mg/kg every 4 weeks seems the most appropriate because of the 50% reduction in relapse rate. In fact, this dose has also been recommended by the last reported guidelines from the National Institute for Health and Clinical Excellence (NICE, UK) and the TOUCH Natalizumab prescribing programme for MS.

Contrast-enhanced MRI is a sensitive method for detecting active lesions. Gd-enhancement is a marker for blood brain barrier breakdown and histologically correlates with the inflammatory phase of lesion development. New lesions in MS are defined as new enhancements in areas that had not been seen in a previous scan \[[@CIT0015]\]. As explained in the introduction, PML is a serious adverse effect reported from patients who received natalizumab, but in the present meta-analysis there was no report of PML from natalizumab. There were two deaths reported in one of the included studies \[[@CIT0013]\] in this meta-analysis but it seems they were not related to natalizumab. As shown in [Table V](#T0005){ref-type="table"}, there was no significant difference between natalizumab and placebo in terms of serious and common adverse events.

According to the NICE guidelines, natalizumab is mostly recommended for the treatment of relapsing-remitting multiple sclerosis (RRMS), although it can be an option for other kinds of MS and it is recommended to continue with it until the clinicians consider it appropriate to stop.

Regarding the updated review of Consensus Reports related to current basic and escalating immunomodulatory treatments in MS, the indication and application of natalizumab should preferably be handled in an MS centre. In addition, it should be administered as monotherapy only in patients with a normal differential blood count with approval of exclusion for infections \[[@CIT0016]\].

In conclusion, it seems that the best method of administration of natalizumab in patients with relapsing MS is 3 or 6 mg/kg every 4 weeks. Current data on the efficacy and safety of natalizumab seem to be insufficient and further clinical trials are needed to obtain more conclusive results \[[@CIT0017]\].
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